[go: up one dir, main page]

MX2019009230A - Composicion que comprende capecitabina de liberacion inmediata y liberacion prolongada. - Google Patents

Composicion que comprende capecitabina de liberacion inmediata y liberacion prolongada.

Info

Publication number
MX2019009230A
MX2019009230A MX2019009230A MX2019009230A MX2019009230A MX 2019009230 A MX2019009230 A MX 2019009230A MX 2019009230 A MX2019009230 A MX 2019009230A MX 2019009230 A MX2019009230 A MX 2019009230A MX 2019009230 A MX2019009230 A MX 2019009230A
Authority
MX
Mexico
Prior art keywords
capecitabine
composition
release
extended
immediate
Prior art date
Application number
MX2019009230A
Other languages
English (en)
Inventor
Patel Piyush
Sehgal Ashish
Gandhi Kashyan
Patel Manish
Chauhan Manish
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of MX2019009230A publication Critical patent/MX2019009230A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de Capecitabina, en donde dicha composición comprende Capecitabina de liberación inmediata y Capecitabina de liberación prolongada. Además, la presente invención describe un procedimiento para la preparación de dicha composición.
MX2019009230A 2017-02-06 2018-02-05 Composicion que comprende capecitabina de liberacion inmediata y liberacion prolongada. MX2019009230A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721004194 2017-02-06
PCT/IB2018/050703 WO2018142359A1 (en) 2017-02-06 2018-02-05 Composition comprising immediate release and extended release capecitabine

Publications (1)

Publication Number Publication Date
MX2019009230A true MX2019009230A (es) 2019-09-10

Family

ID=63040300

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009230A MX2019009230A (es) 2017-02-06 2018-02-05 Composicion que comprende capecitabina de liberacion inmediata y liberacion prolongada.

Country Status (13)

Country Link
US (1) US20190358253A1 (es)
EP (1) EP3576721A4 (es)
JP (1) JP2020514314A (es)
CN (1) CN110290779A (es)
AU (1) AU2018214291A1 (es)
BR (1) BR112019016028A2 (es)
CA (1) CA3051040A1 (es)
CL (1) CL2019002174A1 (es)
IL (1) IL268137A (es)
MX (1) MX2019009230A (es)
PH (1) PH12019501689A1 (es)
RU (1) RU2019126572A (es)
WO (1) WO2018142359A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
WO2006110800A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer
MX2011011596A (es) * 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.
US20200054659A1 (en) * 2015-06-13 2020-02-20 Intas Pharmaceuticals Ltd. Extended release capecitabine capsules
CN104997744B (zh) * 2015-08-04 2018-01-23 青岛市中心医院 一种高稳定性卡培他滨片剂及其制备方法

Also Published As

Publication number Publication date
RU2019126572A (ru) 2021-03-09
AU2018214291A1 (en) 2019-08-01
JP2020514314A (ja) 2020-05-21
EP3576721A4 (en) 2020-07-22
EP3576721A1 (en) 2019-12-11
PH12019501689A1 (en) 2020-03-09
IL268137A (en) 2019-09-26
WO2018142359A1 (en) 2018-08-09
CA3051040A1 (en) 2018-08-09
BR112019016028A2 (pt) 2020-03-31
CN110290779A (zh) 2019-09-27
US20190358253A1 (en) 2019-11-28
CL2019002174A1 (es) 2019-11-29

Similar Documents

Publication Publication Date Title
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
PH12019550235A1 (en) Kinase inhibitors and uses thereof
PH12017502393A1 (en) Glucagon derivative and a composition comprising a long acting conjugate of the same
GEP20207075B (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2017007299A (es) Composiciones en suspension de liberacion prolongada gastroretentivas.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
CR20200154A (es) Enantiómeros de tiazoles sustituidos como compuestos antivirales
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
MX2017015137A (es) Composicion farmaceutica oral de dosis diaria de isotretinoin.
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
TR201721505A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
IN2014CH00840A (es)
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
IN2014MU00916A (es)
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
MX2017015505A (es) Composicion de preparacion solida que contiene pranlukast con biodisponibilidad mejorada y metodo para preparar la misma.
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.
WO2015095659A3 (en) Indirubin solid dispersion composition
EP4582145A3 (en) Solid state forms of ixazomib citrate
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
MX2017016108A (es) Capsulas de capecitabina de liberacion prolongada.
PH12019501689A1 (en) Composition comprising immediate release and extended release capecitabine